BASE scientists are working closely with Vaxxas on the BARDA Patch Forward Prize to deliver mRNA vaccines using high-density microarray patch technology.
With support from Sanofi, BASE will establish mRNA production facilities to help Australian scientists build mRNA vaccines and therapies for Phase-1 clinical trials.
BASE has partnered with Oxford Nanopore Technology to develop nanopore sequencing methods to analyse mRNA vaccine quality control.
Sartorius has partnered with the BASE Facility to co-develop protocols and methods to improve the quality and yield of mRNA synthesis.
BASE is supported by the National Collaborative Research Infrastructure Strategy (NCRIS)
TIA can support the development of your mRNA candidates as part of the Pipeline Accelerator voucher scheme. Successful applicants receive up to $50,000 matching funds to develop mRNA drug candidates with BASE research and manufacturing services.
Research Laboratories
Level 3, AIBN (#75)
The University of Queensland
St Lucia, QLD 4072
Manufacture Facility
Level 6, Translational Research Institute
37 Kent St
Woolloongabba, QLD 4102